ClinicalTrials.gg
CompletedNCT01020565Updated Aug 6, 2010

A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection

A Phase 2 interventional study of Entecavir in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-06.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Planned enrollment
45th of 61
60 · median 109
Started
2003
with 2 others
Phase 2
9 of 64
1 open now
Registered
24th of 64
by date
Lead sponsor
19 of 64
Bristol-Myers Squibb

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 45th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2003, is one of 9 in phase 2, and was the 24th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The objectives of this study are to demonstrate that entecavir has antiviral activity with undetectable at Week 48, and to assess the safety and the pharmacokinetic in Japanese patients given entecavir at each dose of 0.1 and 0.5 mg for 52 weeks

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Documentation of chronic infection by ALL of the following:

    1. Positive for HBsAg OR, negative for IgM core antibody and confirmation of chronic hepatitis B on liver
    2. Positive for HBeAg OR negative for HBeAg
    3. Documented HBV Viremia on 2 or more occasions and at screening visit: Viremia on sample drawn AND HBV DNA of ≥ 10*5* copies/mL by PCR assay at the screening visit
  • in the range of 1.3 to 10 x
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Entecavir (0.1 mg)

    Drug: Entecavir

  • Experimental
    Entecavir (0.5 mg)

    Drug: Entecavir

Interventions

  • Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks

    Also known as: Baraclude, BMS-200475

06

What researchers measure

Primary outcomes

  1. Incidence of clinical adverse events and discontinuations due to adverse events of entecavir at doses of 0.5 and 1 mg

    Time frame: Week 52 (end of dosing) plus 5 days

  2. Incidence of laboratory abnormalities of entecavir at doses of 0.5 and 1 mg for 52 weeks

    Time frame: Week 52 (end of dosing) plus 5 days

  3. Proportion of subjects with reduction in HBV DNA by ≥2 log10 or to undetectable level (<400 copies/mL) by PCR assay

    Time frame: Week 48

Secondary outcomes

  1. Mean change from baseline in log10 HBV DNA measured by PCR assay for each entecavir dose (0.5 and 1 mg) at Week 48

    Time frame: Baseline, Week 48

  2. Proportion of subjects who achieve undetectable HBV DNA (<400 copies/mL) by PCR assay at Week 48

    Time frame: Week 48

  3. Proportion of subjects HBeAg-positive at baseline who have loss of HBeAg from serum at Week 48

    Time frame: Week 48

  4. Proportion of subjects HBeAg-positive at baseline who achieve seroconversion (loss of HBeAg and appearance of HBeAb) at Week 48

    Time frame: Week 48

  5. Proportion of subjects with abnormal ALT at baseline who achieve normalization of serum ALT (<1.25 x ULN) at Week 48

    Time frame: Week 48

  6. Proportion of subjects HBeAg-positive at baseline who have Complete Response [undetectable HBV DNA levels by PCR assay, negative for HBeAg and normal serum ALT] at Week 48

    Time frame: Week 48

  7. Proportion of subjects HBeAg-negative at baseline who have Complete Response [undetectable HBV DNA levels by PCR assay, remain negative for HBeAg and normal serum ALT] at Week 48

    Time frame: Week 48

  8. Proportion of subjects who achieve Complete Response, and remain Complete response for 24 weeks after stopping drug

    Time frame: Week 72

  9. Proportion of subjects w/ histological improvement in liver (improvement in necroinflammatory score (≥2 points decrease, Knodell HAI3 score) & no worsening of fibrosis (≥1 point increase, Knodell fibrosis score) at Wk 48 liver biopsy compared to baseline

    Time frame: Baseline, Week 48

  10. Changes in liver histology as assessed by the New Inuyama Classification for histological assessment of chronic hepatitis

    Time frame: Week 52

  11. Relationship between HBV isolates (genotypes A,B,C, etc.) at baseline and antiviral activity

    Time frame: Week 48, or at end of dosing (up to Week 52)

  12. Incidence of resistance mutations of HBV isolates in subjects who have a rise in HBV DNA (by ≥1 log above the nadir for that subject) while on study drug.

    Time frame: Week 48, or at end of dosing (up to Week 52)

  13. Mutation of HBV DNA polymerase at Week 48 from baseline

    Time frame: Baseline, Week 48

  14. Plasma concentrations of entecavir at selected time points during the treatment period

    Time frame: pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36

  15. Population pharmacokinetic assessment of entecavir developed from concentration-time data obtained from healthy subjects

    Time frame: pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol. 2009 Feb;24(2):255-61. doi: 10.1111/j.1440-1746.2008.05593.x. PubMed 19215336 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Nov 25, 2009
Start
Feb 2003
Primary completionActual
Feb 2005
CompletionActual
Feb 2005
Results delay requested
Jan 29, 2010
Last update
Aug 6, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01020565
First posted
Nov 25, 2009
Start date
Feb 2003
Primary completion
Feb 2005
Completion
Feb 2005
Last update
Aug 6, 2010

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion